How Croatian patients suffering from amyotrophic lateral sclerosis have been turned into medical tourists – a comment on a medical and social phenomenon by Mitrečić, Dinko et al.
443
www.cmj.hr
EDITORIAL 
 
Croat Med J. 2014;55:443-5 
doi: 10.3325/cmj.2014.55.443
How Croatian patients suffering 
from amyotrophic lateral 
sclerosis have been turned into 
medical tourists – a comment 
on a medical and social 
phenomenon
Dinko Mitrečić1, Ervina Bilić2, Srećko Gajović1,3
1Laboratory for Stem Cells, Section of Neurogenetics, 
Cytogenetics, and Developmental Genetics, Croatian Institute for 
Brain Research, University of Zagreb School of Medicine, Zagreb, 
Croatia
dominic@mef.hr
2Referral Center for Neuromuscular Diseases and Clinical 
Electromyoneurography, Department of Neurology, University 
Hospital Center Zagreb, University of Zagreb School of Medicine, 
Croatia
3Croatian Medical Journal, Zagreb, Croatia
In the last few weeks, Croatia has witnessed a rarely seen 
surge of public interest in neurologic disease amyotrophic 
lateral sclerosis (ALS). In a rather organized manner and 
with significant media support, money was raised to send 
Croatian patients suffering from ALS to China to receive 
a treatment referred to as “stem cell therapy.” Even before 
this action, individual Croatian patients, including children 
suffering from a variety of diseases, tried on their own to 
seek this type of “therapy.” What makes the current situa-
tion specific is that a subgroup of patients offered to an-
other group of patients a financially covered “package” for 
a treatment in a hospital in China without consulting their 
doctors or other Croatian medical experts. Upon returning 
home, the patients, together with their doctors and fami-
lies, are now facing consequences of this medical and so-
cial phenomenon.
This action seems to have appeared simultaneously with 
the viral social trend initiated in the USA, “the ALS ice buck-
et challenge,” ie, pouring ice-cold water over someone in 
combination with money donation for ALS associations (1). 
From a number of newspaper articles and TV broadcasts, 
one could get an impression that a competition in empa-
thy was taking place. Many Croatian celebrities were chal-
lenged to spill a bucket of cold water over their heads in 
order to collect money for ALS patients. In parallel, medical 
laics representing several patient organizations appeared 
in prime time shows and talked about this “strange disease 
for which the only hope exists in stem cells clinics in Asia.” 
They expressed their intention to mobilize the nation to 
collect funds and send Croatian patients to China and reg-
istered non-profit organizations to raise funds. Using their 
own support groups and, to the best of our knowledge, 
without consultation with medical experts, they decided 
to send several patients from Croatia to one clinic in China, 
spending a minimum of EUR 50 000 per patient. This clinic 
appeared overnight as a place where ALS can be treated 
and even the national television broadcasted a show with 
a goal to collect the money to send the patients there.
ALS is the most common neurodegenerative disease of 
motor neurons, with a prevalence of 2-5/100 000 people. 
It is characterized by rapidly progressing dying of cortical, 
brainstem, and spinal motor neurons and remains an in-
curable disease, leading to a fatal respiratory failure on av-
erage within 5 years following the diagnosis. Although it 
is not our intention to take away somebody’s hope, it has 
to be clearly said that no one has ever been cured from 
this disease. Pathophysiology of ALS is complex and multi-
factorial. It includes mitochondrial dysfunction, intracellu-
lar protein aggregation, disturbances in RNA metabolism, 
impairment at the level of the axonal transport and at the 
neuromuscular synapse, blood-brain barrier breakdown, 
glial cell reaction/dysfunction and neuroinflammation. In 
5%-10% of patients, ALS is inherited. In these cases, every 
fifth patient carries a detected mutation in superoxide dis-
mutase 1 (SOD1), which has up to now been the most reli-
able and mostly used genetic model for ALS.
Although a national registry for ALS patients does not ex-
ist in Croatia, according to the Croatian Referral Center for 
Neuromuscular Disorders, the number of newly diag-
nosed ALS patients varies from 20 to 30 per year and 
the majority of these cases have sporadic ALS. Di-
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agnosis of ALS is established according to the EFNS (Euro-
pean Federation of Neurological Societies) guidelines: it is 
based on anamnestic data, clinical presentation, electro-
myography, and on exclusion of other similar diseases. Dif-
ferential diagnosis in a patient suspected for ALS is wide 
and the most common diagnoses established prior to the 
typical ALS development are cervical radiculomyelopa-
thy and motor neuropathy (multifocal motor neuropathy 
or axonal motor neuropathy). Even though an absence of 
sensory alteration is mandatory for ALS diagnosis, in pa-
tients who previously had some kind of polyneuropathy 
(eg, diabetic sensory polyneuropathy) it may be difficult to 
recognize superimposed ALS. In some patients, only care-
ful monitoring of clinical and electromyographic changes 
over a prolonged period may give the final diagnosis. The 
only drug prescribed to ALS patients is riluzole – in a stan-
dard dose of 50 mg twice a day.
Interestingly, ALS is probably the most common fear-caus-
ing disease among medical doctors and medical students. 
After a course in Neurology at the Medical School Uni-
versity of Zagreb, 12 medical students per academic year, 
which is 4% of the students in one generation, asked for 
a neurological exam and electromyography (unpublished 
data from the Registry of the Croatian Referral Center for 
Neuromuscular Disorders). We also observed that the 
number of patients with the diagnosis of benign fascicula-
tion syndrome is dramatically rising, which is linked to the 
growing knowledge about ALS, including the recent “the 
ALS ice bucket phenomenon.”
One of the main premises and an essential prerequisite 
of good medical practice is that every new treatment, in-
cluding new types of operation, new drugs, or new (stem) 
cell types, needs to be tested using well defined protocols. 
Every new treatment is thus first tested on experimen-
tal animals, where its potential for translation into clini-
cal practice is evaluated. Data are collected by appropri-
ate experimental procedure and subsequently published 
in peer reviewed journals. Clinical trials, as a continuation 
of preclinical results represent a long, step-wise procedure 
involving patients and healthy volunteers. If during clini-
cal trials there is a money transfer involving patients, mon-
ey can only be given to patients for their participation in 
early testing of procedure, and not taken away from them. 
Patients and their doctors need to be informed about all 
details of the procedure. In the case of cell therapy, the 
basic parameters include the source of stem cells, cell 
types (tested by set of various genetic and immunohis-
tochemical markers), rate of cell differentiation pri-
or to injection, cell number and viability, stem cell trans-
plantation procedure, routes of administration, number of 
treatments, and a well-defined protocol for the treatment 
evaluation.
Based on successful preclinical trials, including pub-
lished discoveries from our own group (first intravascu-
lar injection of stem cells into animals suffering from ALS) 
(2) – stem cell clinical trials on ALS patients have been 
launched. Currently, there are approximately 15 ongoing 
clinical trials in the EU and USA. Most of them are focused 
on intraspinal delivery of fetal/mesenchymal/neural stem 
cells (USA, Italy, Spain) and some use intrathecal delivery 
of autologous bone marrow-derived cells. One of the ma-
jor principles of transparency is that every trial is regis-
tered and well described in a publically available database 
of clinical trials (3). Clinical trial registration is a prerequisite 
for publication of results.
Unfortunately, due to their high and very promising poten-
tial, stem cells are sometimes used in unwanted and non-
ethical ways. This is not surprising since the cell therapy in-
dustry reached a year turnover of one billion dollars (4). Cell 
therapy-based medical tourism is a phenomenon when 
people suffering from fatal diseases search for help in coun-
tries that obviously allow or do not control “stem cell clinics.” 
There, patients can receive cell therapy for numerous dis-
eases with only one prerequisite – if they pay for it.
The Croatian patients suffering from ALS who were re-
ceived “stem cell treatment” in the clinic in China were 
treated in a way incompatible with ethical standards. 
Medical care for them practically did not exist. As many 
of them were in advanced stage of disease, they had to 
be accompanied by someone from Croatia to help them 
even with everyday care including basic hygiene. No one 
explained them anything about the ongoing procedures. 
The medical records that they brought with them to Croa-
tia listed several treatments, the majority of which were 
very general suggestions (eg, to “stop smoking” or to “think 
positively”), but “stem cell therapy” was only mentioned by 
name, with no specifics given. For something that is so 
complex, specific, and potentially dangerous, this is com-
pletely unacceptable. The patients have to be informed 
about all the details of the procedure and they have the 
right that their medical doctors from their countries of ori-
gin can freely communicate with the doctors in those clin-
ics. Omitting the detailed medical records could even be 
done on purpose since to patients secret therapies can 
sound attractive, promising, and almost magic. Unfortu-
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nately, they are only previously unevaluated procedures 
with unproved non-standardized products bearing a high 
risk of side effects.
To prevent such practices, International Society for Stem 
Cell Research published the Patient Handbook on Stem 
Cell Therapies (5). This brochure warns patients about a 
growing fraud in the field of stem cell therapy and advis-
es that only FDA or EMEA registered procedures are reli-
able. The same message is brought by the Croatian Brain 
Council, the national coordination of 25 societies (6). The 
Croatian Brain Council gathers experts in all fields of brain 
research and brain therapy and represents an appropri-
ate starting point for any action aimed toward less known 
or less standardized procedures. Stem cell medical tour-
ism brings negative consequences for both patients and 
medical experts. While patients are in danger of compli-
cations arising from not well controlled procedures, hard 
work and continuous progress of researchers who adhere 
to the principles of good medical practice are in jeopar-
dy to be declared slow and inefficient. The failure of un-
approved and uncontrolled stem cell treatment can cre-
ate a wrong impression that stem cell based therapy has 
no potential and that funding of stem cell research is not 
bringing results.
Although the authors understand the hope that all of a 
sudden a cure for ALS would appear, we express our con-
cerns for patients. It is of vital significance that the medical 
community shares information about the disease, treat-
ment possibilities, and new research trends to the pub-
lic. Such evidence-based information needs to be used 
to confront the well marketed, immediate, costly, and po-
tentially dangerous trend of “medical tourism” in search for 
stem cell therapies. The current example shows that the 
decisions about the patients are not only in the hands of 
the doctors, but that there are many stakeholders involved. 
This does not only include the patients and their families, 
but also the charities, media, politicians, and many other 
compassionate individuals. The complexity of the deci-
sion-making process turns the patients into “bioobjects,” a 
phenomenon explained in a recent series of articles in the 
Croatian Medical Journal (7,8).
Instead of investing wisely into further development of 
stem cell research and medical standards in Croatia, funds 
raised from Croatian citizens, already heavily hit by the on-
going financial crisis, were wasted due to the false prom-
ises and ignorance. Thus we faced two losses: the funds 
were spent in vain and the patients were put in jeopardy. 
Therefore, we urge that future action for ALS or other dis-
eases should be coordinated in communication with the 
doctors who treat the patients and in consultation with ex-
perts who are working in this field. They have dedicated 
their lives to a major goal: to help and not to harm their 
patients.
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